Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Intrinsic Therapeutics | Formerly MedGenesis Inc

Request full access

Manufacturer of Barricaid Annular Closure. Designed to prevent reherniation

Woburn, United StatesFounded 2000Biotech & Life Sciences

About Intrinsic Therapeutics | Formerly MedGenesis Inc

Intrinsic Therapeutics, Inc. is a medical device company established in 2000, operating from Woburn, Massachusetts. The company's inception is credited to Greg Lambrecht, who was inspired to find a better solution for recurrent disc herniations after witnessing his mother's experience with the condition. Lambrecht, an inventor with a background in Mechanical and Nuclear Engineering from MIT, also founded other medical device companies, including Coravin and Viacor, and held significant roles at Stryker and Pfizer's Medical Technology Group.

The company's core business revolves around the development and commercialization of the Barricaid® Annular Closure Device, a spinal implant designed to address a significant unmet need in spinal surgery. The Barricaid is intended for patients undergoing lumbar discectomy, a common procedure to treat herniated discs. It aims to reduce the high rate of reherniation and subsequent reoperations by closing the defect left in the outer wall of the disc (the annulus fibrosus) after surgery. The target clients are primarily surgeons and healthcare professionals who perform these spinal procedures. Revenue is generated through the sale of the Barricaid device, which is marketed through distributors in Europe, Australia, Mexico, the Middle East, and other regions, as well as in the United States.

The Barricaid device is a permanent implant with two main components: a titanium bone anchor that secures the device to an adjacent vertebral body and a flexible polymer barrier designed to block the hole in the annulus. This design is engineered to withstand the pressure within the spinal disc while allowing for normal anatomical movement post-surgery. The device received FDA Pre-Market Approval (PMA) in 2019, a significant milestone that followed a rigorous, multi-center, randomized superiority trial involving 554 patients. This study demonstrated that Barricaid was superior to the standard discectomy procedure alone in reducing reherniation and reoperation rates. As of June 2025, the device has been implanted in over 12,000 patients and was used for the first time in an endoscopic approach. The company has secured substantial funding to support its operations, including a $49 million round in 2017 and a $52 million round in 2019, with investors like New Enterprise Associates (NEA), Questa Capital, and Delos Capital.

Source: Dealroom company data

At a glance

Status
Operational
Employees
91
Open positions
None listed
Dealroom signal
77.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology, Medical Devices
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Apr 2023 $5.9M $260M Undisclosed ↗
SERIES EOther financing Apr 2019 $52M $208M NEA · Greenspring Associates · Delos Capital · Quadrille Capital —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Intrinsic Therapeutics | Formerly MedGenesis Inc website traffic

Latest recorded traffic for Intrinsic Therapeutics | Formerly MedGenesis Inc is 0 monthly website visits. Intrinsic Therapeutics | Formerly MedGenesis Inc's team grew 5.8% over the past year.

Latest monthly visits0 1-year team growth+5.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Intrinsic Therapeutics | Formerly MedGenesis Inc in the Woburn ecosystem

Live from Dealroom

The Intrinsic Therapeutics | Formerly MedGenesis Inc office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Series B and later4 investors entered at this stage

Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States95.5%
🇩🇪 Germany3%
🇦🇪 United Arab Emirates1.5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Intrinsic Therapeutics | Formerly MedGenesis Inc on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Intrinsic Therapeutics | Formerly MedGenesis Inc’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.